Gliclazide is a hypoglycemic agent of the sulfonylurea group. Its hypoglycemic action is related to an improvement in insulin secretion from the functioning beta cells of the pancreas. It potentiates the insulin release and improves the dynamics of insulin.
Gliclazide belongs to the group of intermediate acting hypoglycaemic agents. It is rapidly absorbed from the GIT, and is metabolised in the liver. It appears in the blood within 1-2 hrs. It is extensively plasma protein bound ( more than 90%). Peak level is achieved in 4-6 hrs. The plasma t 1/2 is 8-12 hrs and its duration of action is 12 hrs.
Gliclazide is a second generation sulphonylurea which acts via stimulating beta cells of the islet of Langerhans of pancreas to release insulin. Gliclazide also enhances peripheral insulin sensitivity. Metformin enhance peripheral glucose uptake by the tissues and its utilisation. It also reduces hepatic glucose production. Metformin diminished insulin resistance. Gliclazide is a hypoglycaemic agent of the sulphonylurea group. It stimulates insulin secretion from functional pancreatic beta-cells and increases the sensitivity of the beta-cells to a glucose stimulus. Some residual beta-cell function is therefore necessary. Gliclazide restores the diminished first-phase of insulin secretion noted in non-insulin dependant diabetes mellitus. Any long-term hypoglycaemic activity of gliclazide can be attributed to an ability to maintain its effect on insulin secretion. Extrapancreatic effects may also be involved in the long-term efficacy of gliclazide. These effects include improvement in insulin mediated glucose utilisation and potentiation of postreceptor insulin sensitive pathways.
Gliclazide is a sulphonylurea hypoglycaemic given orally for non-insulin dependent diabetes mellitus (type 2). Gliclazide stimulates the secretion of insulin from functional pancreatic β-cells, increasing the sensitivity of β-cells to glucose stimulation. Diminished first-phase insulin secretion is increased by gliclazide in type 2 diabetes mellitus.
Gliclazide may be able to maintain its effect on insulin secretion resulting in long-term hypoglycaemic activity and some extrapancreatic effects. Such extrapancreatic effects include potentiation of post-receptor insulin sensitive pathways and improvement of insulin mediated glucose utilisation. Gliclazide also reduces platelet adhesiveness and aggregation at normal therapeutic doses in man.